Cell Regulation with Polyvalent Nanoparticles

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA8650-11-M-6211
Agency Tracking Number: F103-043-2330
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2010
Solicitation Topic Code: AF103-043
Solicitation Number: 2010.3
Small Business Information
AuraSense, LLC
1801 Maple Avenue, Suite 4301, Evanston, IL, -
DUNS: 831421958
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 David Giljohann
 Research Scientist
 (847) 467-2874
Business Contact
 Percy Crocker
Title: VP Commercial Development
Phone: (847) 467-2874
Email: pcrocker@aurasense.com
Research Institution
ABSTRACT: Polyvalent nanoparticle constructs have unique properties that make them ideal for gene regulation applications, while overcoming many of the challenges which have prevented oligonucleotides from being developed into viable therapies. Specifically, AuraSense is developing constructs which are highly resistant to nuclease digestion, have high binding constants for intracellular targets, and, uniquely, have exhibited high entry into every cell type tested to date (over 50 cell types including primary cells, tissues and neurons). The AuraSense constructs thus represent a significant advance in gene pathway regulation technology while displaying the characteristics of an ideal gene therapy system. Building on our initial success, we are proposing to develop optimal constructs for application in the control of gene and protein expression. Objective 1 experiments will be designed to demonstrate and optimize: 1) Ability to deliver conjugate nanostructures into both prokaryotic and eukaryotic cells, 2) Ability to deliver oligonucleotides including siRNA, DNA and modified nucleic acid structures, and 3) Qualitative and quantitative assessment of cellular entry. Objective 2 will determine the 1) Functional gene regulatory effect in prokaryotic and eukaryotic cells, 2) Biological compatibility and toxicity, and 3) Comparison with commercially available lipid and polymer systems (e.g. Lipofectin and Cytofectin). BENEFIT: AuraSense"s nanoparticle constructs have great potential as broadly effective, non-toxic agents for cellular transfection of genetic material. AuraSense nanoparticle technology has been developed in numerous proof-of-concept applications and has been the subject of consistent commercial interest to date. This platform stands to significantly advance transfection as a tool for life science researchers and for increasing the safety of troops in the field. AuraSense"s nanoparticle platforms are highly relevant to two markets: Chemical Transfection (as used for research applications) and Biodefense.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government